Eli Lilly and Company has announced the appointment of two new Executive Committee members and the expansion of other senior leaders’ roles to drive the company’s next phase of growth, accelerate its ambitious pipeline, create new portfolio opportunities and strengthen patient access to its medicines.

Carole Ho will join Lilly as executive vice president and president of Lilly Neuroscience, and will also serve on the company’s Executive Committee. With more than two decades of biopharmaceutical experience spanning neurology, rare diseases and immunology, Ho most recently served as chief medical officer and head of development at Denali Therapeutics, where she led the company’s translational medicine and clinical development strategy.

Adrienne Brown, currently group vice president of corporate business development at Lilly, has been promoted to executive vice president and president of Lilly Immunology, joining the Executive Committee. Over her 20-year career at Lilly, Brown has held a range of leadership roles across the US and Japan operations, including business development, sales, marketing and commercial strategy, including leading the US launch of Mounjaro.  

In addition, Daniel Skovronsky will take on an expanded role as chief scientific and product officer and president of Lilly Research Laboratories, overseeing research and development as well as global launches and product strategy for Cardiometabolic Health, Immunology and Neuroscience. He will continue to report directly to David A. Ricks, Lilly’s chair and CEO, and remain on the Executive Committee.  

New Executive Committee members Ho and Brown and continuing Executive Committee member Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, will report to Skovronsky.

Jacob Van Naarden, executive vice president and president of Lilly Oncology, will also see his responsibilities broadened as the corporate business development function moves under his leadership. He will continue to report to directly to Ricks and remain on the Executive Committee.  

Commenting on the appointments, Ricks said, "In recent years, Lilly has transformed our research engine, sped development and launched breakthrough medicines while dramatically expanding production capacity and improving access to care and affordability. Looking ahead, we see an even greater opportunity to help people live better lives and grow our company and its impact.”

He added that the addition of Ho and Brown, alongside the expanded roles of Skovronsky and Van Naarden, will help Lilly convert its long-term potential into reality.